What are future therapeutic combinations in follicular lymphoma?
In this video, the panel discusses promising future combinations in follicular lymphoma, highlighting novel agents paired with rituximab, bispecific antibodies, and CELMoDs like
Lymphoma Roundtable
Cellular Therapy
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
Leukemia
Myelodysplastic Syndromes
News
Is unrelated cord blood better than bone marrow in haploidentical transplantation?
Haploidentical transplantation combined with unrelated cord blood resulted in superior one-year disease-free survival compared with the same transplant using bone marrow in patients
Cellular Therapy
Lymphoma
Indolent B-Cell Lymphomas
News
Liso-cel receives positive CHMP opinion in relapsed or refractory follicular lymphoma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of lisocabtagene maraleucel (lise-cel) for
Leukemia
Chronic Lymphocytic Leukemia
Longer-term ALPINE results show ‘sustained PFS benefit’ with zanubrutinib for CLL/SLL
After a median follow-up of 42.5 months, zanubrutinib resulted in a sustained progression-free survival (PFS) benefit compared with ibrutinib, with responses deepening over
Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
FDA grants Orphan Drug Designation to CD5-targeted CAR-T cell therapy for T-cell lymphoma
The US Food and Drug Administration (FDA) granted Orphan Drug designation to MB-105, a CD5-targeted chimeric antigen receptor (CAR)-T cell therapy, for the
Leukemia
Acute Myeloid Leukemia
News
Bone marrow microenvironment boosts AML patients’ response to donor lymphocyte infusion
Differences in the bone marrow microenvironment may determine why some relapsed acute myeloid leukemia (AML) patients respond better to donor lymphocyte infusion (DLI)
Myeloproliferative Neoplasms
Primary Myelofibrosis
Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?
A study found that “pacritinib may offer a unique survival advantage” for patients with myelofibrosis (MF) and thrombocytopenia who achieve any spleen volume
Cellular Therapy
Multiple Myeloma
News
CARTITUDE-4 findings show improved health-related quality of life with cilta-cel for multiple myeloma
Results of the CARTITUDE-4 trial assessing patient-reported outcomes in those with multiple myeloma receiving the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel
66th American Society of Hematology Annual Meeting & Exposition
MDS
Preliminary TakeAim data shows promise of emavusertib in higher-risk MDS
The IRAK-4 inhibitor emavusertib showed encouraging clinical activity in patients with higher-risk myelodysplastic syndromes (MDS), according to preliminary data from the phase 1/2
Lymphoma
Aggressive B-Cell Lymphomas
News
Presence of circulating lymphoma cells a significant adverse risk factor in DLBCL
The largest study to date evaluating the impact of circulating lymphoma cells (CL) on outcomes in patients with newly diagnosed de novo diffuse